Literature DB >> 19035483

Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Yu Cheng1, Jin Woo Kim, Wennuan Liu, Thomas A Dunn, Jun Luo, Matthew J Loza, Seong-Tae Kim, Siqun Lilly Zheng, Jianfeng Xu, William B Isaacs, Bao-Li Chang.   

Abstract

BACKGROUND: TNFRSF10C, is located on 8p21.3, one of the most frequently deleted loci in the genome of prostate cancer (PCa). Hypermethylation of TNFRSF10C promoter CpG island (CGI) had been reported in many tumors including PCa. However, the interplay between somatic deletion and promoter hypermethylation of TNFRSF10C on PCa development has not been investigated.
METHODS: Methylation status of promoter CGI and deletion status of the TNFRSF10C locus was investigated by bisulfite sequencing and Affymetrix SNP array, respectively, in 59 pairs of PCa tumor and matched normal samples with three PCa cell lines. TNFRSF10C gene expression changes in relation to cancer-associated genetic/epigenetic changes in clinical specimens, and change of TNFRSF10C expression before and after 5-aza-2'-deoxycytidine treatment in the PC3 PCa cell line was assessed by real-time RT-PCR.
RESULTS: We found that TNFRSF10C promoter CGI was differentially methylated in 46 of 59 primary cancers (78.0%). Hemizygous deletion at TNFRSF10C was found in 44 of the 59 prostate tumors (74.5%). Interestingly, in 94.9% of the tumors (56 out of 59), TNFRSF10C was either hemizygously deleted or its promoter CGI hypermethylated. Deletion and/or methylation of the TNFRSF10C gene were correlated with decreased mRNA expression of the gene in clinical specimens. Demethylation of the TNFRSF10C promoter CGI was accompanied by transcriptional re-activation of TNFRSF10C in the PCa cell line PC3.
CONCLUSION: We found a notably high frequency of promoter CGI methylation and deletion of TNFRSF10C in PCa tissues. Our results indicated that inactivation of TNFRSF10C by chromosomal deletion and promoter methylation may play an important role in PCa development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19035483      PMCID: PMC2795318          DOI: 10.1002/pros.20882

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  32 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Prostate cancer.

Authors:  William G Nelson; Angelo M De Marzo; William B Isaacs
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

Review 3.  Rel/NF-kappaB/IkappaB proteins and cancer.

Authors:  T D Gilmore; M Koedood; K A Piffat; D W White
Journal:  Oncogene       Date:  1996-10-03       Impact factor: 9.867

4.  Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells.

Authors:  Emmanuelle Charafe-Jauffret; Jean-François Moulin; Christophe Ginestier; Didier Bechlian; Nathalie Conte; Jeannine Geneix; José Adélaïde; Tetsuro Noguchi; Jacques Hassoun; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Int J Oncol       Date:  2002-11       Impact factor: 5.650

5.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer.

Authors:  G S Bova; B S Carter; M J Bussemakers; M Emi; Y Fujiwara; N Kyprianou; S C Jacobs; J C Robinson; J I Epstein; P C Walsh
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  Identification and resolution of artifacts in bisulfite sequencing.

Authors:  Peter M Warnecke; Clare Stirzaker; Jenny Song; Christoph Grunau; John R Melki; Susan J Clark
Journal:  Methods       Date:  2002-06       Impact factor: 3.608

7.  Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors.

Authors:  Hassan Chaib; James W MacDonald; Robert L Vessella; Joseph G Washburn; Janna E Quinn; Austin Odman; Mark A Rubin; Jill A Macoska
Journal:  Genes Chromosomes Cancer       Date:  2003-07       Impact factor: 5.006

8.  Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.

Authors:  Wennuan Liu; Bao-Li Chang; Scott Cramer; Patrick P Koty; Tao Li; Jishan Sun; Aubrey R Turner; Chris Von Kap-Herr; Peggy Bobby; Jianyu Rao; S Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.

Authors:  Narayan Shivapurkar; Shinichi Toyooka; Kiyomi O Toyooka; Jyotsna Reddy; Kuniharu Miyajima; Makoto Suzuki; Hisayuki Shigematsu; Takao Takahashi; Gunjan Parikh; Harvey I Pass; Preet M Chaudhary; Adi F Gazdar
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

10.  Biallelic inactivation of the RIZ1 gene in human gastric cancer.

Authors:  Yutaka Tokumaru; Shuji Nomoto; Carmen Jerónimo; Rui Henrique; Susan Harden; Barry Trink; David Sidransky
Journal:  Oncogene       Date:  2003-10-09       Impact factor: 9.867

View more
  14 in total

Review 1.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

2.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

3.  MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Jennifer M Siu; Edmond S K Ma; Ava Kwong
Journal:  Tumour Biol       Date:  2013-11-13

Review 4.  DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Authors:  Mohammad Obaidul Hoque
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

5.  The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.

Authors:  Wensheng Zhang; Andrea Edwards; Wei Fan; Erik K Flemington; Kun Zhang
Journal:  Comput Biol Chem       Date:  2016-02-27       Impact factor: 2.877

6.  TNFRSF10C copy number variation is associated with metastatic colorectal cancer.

Authors:  Daniel G Tanenbaum; William A Hall; Lauren E Colbert; Amanda J Bastien; Daniel J Brat; Jun Kong; Sungjin Kim; Bhakti Dwivedi; Jeanne Kowalski; Jerome C Landry; David S Yu
Journal:  J Gastrointest Oncol       Date:  2016-06

7.  Aberrant DNA methylation and prostate cancer.

Authors:  Sunipa Majumdar; Eric Buckles; John Estrada; Shahriar Koochekpour
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

8.  Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study.

Authors:  Albertas Dauksa; Antanas Gulbinas; Giedrius Barauskas; Juozas Pundzius; Johannes Oldenburg; Osman El-Maarri
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

9.  DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients.

Authors:  Érica S S de Araújo; Dimitrius T Pramio; André Y Kashiwabara; Paula C Pennacchi; Silvya S Maria-Engler; Maria I Achatz; Antonio H J F M Campos; João P Duprat; Carla Rosenberg; Dirce M Carraro; Ana C V Krepischi
Journal:  Biomed Res Int       Date:  2015-04-12       Impact factor: 3.411

10.  GATA4 and DcR1 methylation in glioblastomas.

Authors:  Paulina Vaitkienė; Daina Skiriutė; Kęstutis Skauminas; Arimantas Tamašauskas
Journal:  Diagn Pathol       Date:  2013-01-15       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.